Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

0 Umsagnir
0
Episode
598 of 1000
Lengd
16Mín.
Tungumál
enska
Gerð
Flokkur
Viðskiptabækur

Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.

Further Listening:

Trillion Dollar Shot

Why WeightWatchers Wants in on Drugs Like Ozempic

Sign up for WSJ’s free What’s News newsletter.

Learn more about your ad choices. Visit megaphone.fm/adchoices


Hlustaðu og lestu

Stígðu inn í heim af óteljandi sögum

  • Lestu og hlustaðu eins mikið og þú vilt
  • Þúsundir titla
  • Getur sagt upp hvenær sem er
  • Engin skuldbinding
Prófa frítt
is Device Banner Block 894x1036
Cover for Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Other podcasts you might like ...